Skip to main content

Table 2 Distribution of relapse risk in non-treated and treated patients, according to treatment strategies

From: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Variables

Non-treated

N = 59

aTreated

N = 57

Treatment strategy

Type I IS

N = 40

Patients with clinical relapse, n (%)

28 (47.5)

27 (47.4)

14 (35.0)

Time from first relapse to treatment, months, median (range)

–

5.0 (0–532.6)

5.1 (0–532.6)

bTime from T0 to relapse, months, median (range)

7.9 (0.1–84.2)

15.1 (0.5–211.1)

21.9 (0.5–94.1)

Treatment duration, months, median (range)

–

22.3 (6.0–176.1)

22.2 (6.0–151.0)

HR, crude (95%CI)

–

0.58 (0.34–0.99),

p = 0.050

0.40 (0.21–0.77),

p = 0.006

HR, propensity score (95%CI)

–

0.68 (0.40–1.16),

p = 0.155

0.41 (0.20–0.82)

p = 0.011

  1. *PS-weighted proportional hazards Cox models were not used in the other groups due to the low number of patients
  2. aAmong treated patients (n = 57), 9 patients were excluded since started treatment before the first relapse
  3. bT0 was defined as the date of treatment initiation for treated patients and as the date of relapsing ADS diagnosis (date of the first relapse) for non-treated patients
  4. HR hazard ratio, CI confidence interval, IS immunosuppressants
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094